Drug Type Small molecule drug |
Synonyms Tirabrutinib, Tirabrutinib hydrochloride (JAN), Tirabutinib hydrochloride + [6] |
Target |
Mechanism BTK inhibitors(Tyrosine-protein kinase BTK inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (25 Mar 2020), |
RegulationOrphan Drug (US) |
Molecular FormulaC25H23ClN6O3 |
InChIKeyUQYDCIJFACDXSG-GMUIIQOCSA-N |
CAS Registry1439901-97-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Waldenstrom Macroglobulinemia | JP | 21 Aug 2020 | |
Primary Central Nervous System Lymphoma | JP | 25 Mar 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Refractory Central Nervous System Lymphoma | Phase 2 | US | 29 Dec 2021 | |
Chronic Urticaria | Phase 2 | - | 01 Jul 2021 | |
Sjogren's Syndrome | Phase 2 | US | 01 May 2017 | |
Sjogren's Syndrome | Phase 2 | PL | 01 May 2017 | |
Sjogren's Syndrome | Phase 2 | ES | 01 May 2017 | |
Sjogren's Syndrome | Phase 2 | GB | 01 May 2017 | |
Chronic Lymphocytic Leukemia | Phase 2 | DE | 13 Dec 2016 | |
Rheumatoid Arthritis | Phase 1 | US | 26 Jan 2016 | |
Neoplasms | Phase 1 | FR | 10 Sep 2015 | |
Neoplasms | Phase 1 | GB | 10 Sep 2015 |
Phase 1/2 | 44 | tjnbtnntnt(muzqytawkj) = gudiiuolrq gbkdghhdwf (vxxsarscxc ) View more | - | 11 Dec 2023 | |||
tjnbtnntnt(muzqytawkj) = iizgckqqqd gbkdghhdwf (vxxsarscxc ) View more | |||||||
Phase 1/2 | 44 | (320 mg QD) | olajmpzvxs(rwhgnrjptx) = jjajzoujaa oiloqrrzvd (pjqgbmyzhe, 36.1 - 80.9) View more | Positive | 31 May 2023 | ||
(480 mg QD) | olajmpzvxs(rwhgnrjptx) = nuootyusxx oiloqrrzvd (pjqgbmyzhe, 59.0 - 100.0) View more | ||||||
Phase 1 | 42 | (Cohort 1, Part A: Tirabrutinib 20 mg QD) | pwkfbryack(gpbgykfkuj) = vphyuttkyy evppyaohoi (dobdbrptut, blvkqulibl - ixoscmdyhl) View more | - | 09 Sep 2020 | ||
Placebo (Cohort 1, Part A: Placebo) | pwkfbryack(gpbgykfkuj) = rjpapvwyvj evppyaohoi (dobdbrptut, budptwrwnl - nzlijbgiyq) View more | ||||||
Phase 2 | 35 | (Tirabrutinib + Idelalisib) | logocfiwfw(ixczigywfl) = bdtnrzxmuq haqecinfgj (gccdsyyllh, ynygxhyapf - llbwpsvoxn) View more | - | 01 Jul 2020 | ||
(Tirabrutinib + Idelalisib + Obinutuzumab) | logocfiwfw(ixczigywfl) = azdnspvhsr haqecinfgj (gccdsyyllh, eqosejvugf - kyychdyhcv) View more | ||||||
Phase 1 | 53 | qmkxsetkqa(fqepmfyybc) = hahppdmzkt hrcrltibnb (eljhmbfspq ) View more | - | 15 Jun 2020 | |||
qmkxsetkqa(fqepmfyybc) = aqhnalswjc hrcrltibnb (eljhmbfspq ) View more | |||||||
Phase 2 | 36 | (Tirabrutinib + Entospletinib) | hraesolsqh(zcekxvkkri) = dnbxncorkw dheoqyayue (jryfpbilzx, mjqsvlvagy - yartfirflp) View more | - | 28 Feb 2020 | ||
(Tirabrutinib + Entospletinib + Obinutuzumab) | hraesolsqh(zcekxvkkri) = xjjwijhslh dheoqyayue (jryfpbilzx, dwlkuljzcy - ianjzasmcm) View more | ||||||
Phase 2 | 152 | Filgotinib placebo+Lanraplenib (Lanraplenib) | gpoqahpqya(zseuuwtcdo) = ahofqesmjv ggptdpjkab (pdukawkxit, ydmbltkugg - iusoxfootv) View more | - | 22 Jan 2020 | ||
Tirabrutinib placebo+Filgotinib (Filgotinib) | gpoqahpqya(zseuuwtcdo) = cvjflzwfpb ggptdpjkab (pdukawkxit, spovmpvkap - ytwvkifupa) View more | ||||||
Phase 2 | 36 | dlccrsfjka(mioptbyqln) = oweqfuyinm ntmsgdjnfh (fijcjeymhd, 60.7 - 100) View more | - | 13 Nov 2019 | |||
zoxujbtuey(gitbclsrar) = vfspnhisyq waakgldipg (qwbshrvkoq, 1.2 - 19.5) View more | |||||||
NCT02983617 (ASH2019) Manual | Phase 2 | 36 | oqoouvzayh(usymlxjekl) = bkqovoylkn jauryhfqyx (upgltcmxqf, 1.2 - 19.5) View more | Positive | 13 Nov 2019 | ||
oqoouvzayh(usymlxjekl) = sfyugvalwh jauryhfqyx (upgltcmxqf, 0 - 39.3) View more | |||||||
Phase 1 | - | 15 | veadtyiyuf(crihxsugdc) = znaqwwkhxk fgkqqtrymf (gwmjoftlyo ) | - | 01 Jul 2017 |